Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445315 | 0.88 | L3MBTL1 (0.57) | L3MBTL1AGTR1KDM4EUBE2NALOX5 | |
| SCHEMBL8188816 | 0.83 | AGTR1 (0.66) | L3MBTL1AGTR1KDM4EUBE2NALOX5 | |
| SCHEMBL5434539 | 0.81 | AGTR1 (0.51) | L3MBTL1AGTR1ALOX5HTR6PTGS2 | |
| SCHEMBL3331994 | 0.80 | HTR6 (0.50) | L3MBTL1KDM4EUBE2NALOX5HTR6 | |
| SCHEMBL28184674 | 0.77 | AGTR1 (0.60) | L3MBTL1AGTR1KDM4EUBE2NALOX5 | |
| SCHEMBL20505521 | 0.77 | AGTR1 (0.60) | L3MBTL1AGTR1KDM4EUBE2NALOX5 | |
| SCHEMBL12748306 | 0.77 | AKR1C3 (0.78) | L3MBTL1KDM4EUBE2NALOX5HTR6 | |
| SCHEMBL29414776 | 0.77 | AKR1C3 (0.78) | L3MBTL1KDM4EUBE2NALOX5HTR6 | |
| SCHEMBL3335935 | 0.74 | MAPT (0.48) | AGTR1KDM4EHTR6 | |
| SCHEMBL13302218 | 0.73 | ALOX5 (0.68) | L3MBTL1KDM4EUBE2NALOX5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | L3MBTL1 411/4885AGTR1 4033/4885KDM4E 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.